Journal
BMC CANCER
Volume 22, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12885-022-09572-7
Keywords
HIPEC; Peritoneal carcinomatosis; Peritoneal metastases; Colon cancer
Categories
Funding
- Hospital Universitario de Fuenlabrada (Madrid, Spain)
- Sociedad Espanola de Oncologia Quirurgica
- Asociacion Espanola de Cirujanos
Ask authors/readers for more resources
The French PRODIGE 7 trial raised doubts about the specific survival benefit of HIPEC with oxaliplatin for colorectal cancer peritoneal metastases. The GECOP-MMC trial aims to evaluate the effectiveness of HIPEC with high-dose mytomicin-C in preventing peritoneal recurrence in limited peritoneal metastasis from colon cancer. The primary endpoint is 3-year peritoneal recurrence-free survival.
Background: The French PRODIGE 7 trial, published on January 2021, has raised doubts about the specific survival benefit provided by HIPEC with oxaliplatin 460 mg/m(2) (30 minutes) for the treatment of peritoneal metastases from colorectal cancer. However, several methodological flaws have been identified in PRODIGE 7, specially the HIPEC protocol or the choice of overall survival as the main endpoint, so its results have not been assumed as definitive, emphasizing the need for further research on HIPEC. It seems that the HIPEC protocol with high-dose mytomicin-C (35 mg/m(2)) is the preferred regime to evaluate in future clinical studies. Methods: GECOP-MMC is a prospective, open-label, randomized, multicenter phase IV clinical trial that aims to evaluate the effectiveness of HIPEC with high-dose mytomicin-C in preventing the development of peritoneal recurrence in patients with limited peritoneal metastasis from colon cancer (not rectal), after complete surgical cytoreduction. This study will be performed in 31 Spanish HIPEC centres, starting in March 2022. Additional international recruiting centres are under consideration. Two hundred sixteen patients with PCI <= 20, in which complete cytoreduction (CCS 0) has been obtained, will be randomized intraoperatively to arm 1 (with HIPEC) or arm 2 (without HIPEC). We will stratified randomization by surgical PCI (1-10; 11-15; 16-20). Patients in both arms will be treated with personalized systemic chemotherapy. Primary endpoint is peritoneal recurrence-free survival at 3 years. An ancillary study will evaluate the correlation between surgical and pathological PCI, comparing their respective prognostic values. Discussion: HIPEC with high-dose mytomicin-C, in patients with limited (PCI <= 20) and completely resected (CCS 0) peritoneal metastases, is assumed to reduce the expected risk of peritoneal recurrence from 50 to 30% at 3 years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available